These results suggest that GADD45β−l specifically inhibits MKK7 pathway, without blocking MKK4, and this inhibition leads to a significant neuroprotection in vivo, with a temporal intervention window of 6 h after cerebral ischemia. The gene discussed is MAP2K4; the disease is brain ischemia.